Vaxcyte, Inc.

Vaxcyte, Inc.

54.50
EUR
-1.00
(-1.80%)
-7.19EPS
7.05BMarket Cap
Mar 02Next Earn

Total Valuation

EUR

As of September 30, 2026, Vaxcyte, Inc. carries a market capitalization of 7.05B, placing it among publicly traded companies globally. Its enterprise value stands at 6.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.05B
Enterprise Value6.10B

Important Dates

Vaxcyte, Inc.'s next confirmed earnings release is scheduled for March 2, 2027.

Earnings Date3/2/2027

Share Statistics

As of September 30, 2026, Vaxcyte, Inc. has 149.30M shares outstanding.

Shares Outstanding149.30M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio3.21
P/TBV Ratio3.21
P/FCF Ratio-7.58
P/OCF Ratio-7.84

Financial Position

As of September 30, 2026, Vaxcyte, Inc. maintains a current ratio of 4.56, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Current Ratio4.56
Quick Ratio4.37
Debt / Equity8.91
Debt / EBITDA-0.19

Financial Efficiency

Over the twelve months ended September 30, 2026, Vaxcyte, Inc. posted a negative return on equity (ROE) of -42.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.28, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 507.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-42.68
Return on Assets (ROA)-37.28
Employee Count507.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, Vaxcyte, Inc.'s stock has gained approximately 30.38% over the past 52 weeks. The 50-day moving average sits at 53.34, while the 200-day moving average is 49.17.

52-Week Price Change30.38%
50-Day Moving Average53.34
200-Day Moving Average49.17

Income Statement

EUR

Over the twelve months ended September 30, 2026, Vaxcyte, Inc. generated - - in revenue and converted that into -1.01B in net income, yielding earnings per share of -7.19. EBITDA reached -1.06B, while operating income came in at -1.09B.

Operating Income-1.09B
Pretax Income-1.01B
Net Income-1.01B
EBITDA-1.06B
EBIT-1.09B
Earnings Per Share (EPS)-7.19

Balance Sheet

EUR

As of September 30, 2026, Vaxcyte, Inc. holds 1.14B in cash and equivalents against 195.73M in total debt, resulting in a net debt position of -110.70M. Total book value stands at 2.20B, with working capital of 929.82M providing operational flexibility.

Cash & Cash Equivalents1.14B
Total Debt195.73M
Net Debt-110.70M
Equity (Book Value)2.20B
Book Value Per Share14.71
Working Capital929.82M

Cash Flow

EUR

Vaxcyte, Inc. produced -848.78M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -28.90M in capital expenditures, free cash flow totaled -877.68M - equivalent to -6.23 per share.

Operating Cash Flow-848.78M
Capital Expenditures-28.90M
Free Cash Flow-877.68M
FCF Per Share-6.23

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -13.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.57, meaning Vaxcyte, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-7.57
FCF Yield-13.19

Scores

As of September 30, 2026, Vaxcyte, Inc. has an Altman Z-Score of 7.22, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.22